XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 01, 2023
Apr. 01, 2023
Jul. 07, 2019
Aug. 27, 2018
Dec. 31, 2022
Jul. 31, 2022
Apr. 30, 2022
May 31, 2020
Apr. 30, 2020
Oct. 31, 2019
May 31, 2019
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Aug. 31, 2023
Apr. 04, 2022
Loss Contingencies [Line Items]                                      
Payment of cash                             $ 9,942,750 $ 2,191,919      
Proceeds from royalties received                             50,250        
Annual royalty obligation                             $ 4,020        
Cash consideration   $ 16,792,037                                  
Options to acquire shares             144,191                      
Weighted exercise price             $ 10.71                        
Warrants to purchase shares             4,424                        
Exercise price             $ 7.32                        
Expiration date             Apr. 22, 2031                        
Payments receive   $ 893,000                                  
cash                                   $ 693,000  
Cash consideration           $ 10,000,000.0                          
Number of shares           486,145                          
Net income                       $ (34,579)   $ (58,792) $ (111,455) (98,485)      
Cash Closing Consideration [Member]                                      
Loss Contingencies [Line Items]                                      
Payments to Acquire Productive Assets $ 15,250,000                                    
Common Stock [Member]                                      
Loss Contingencies [Line Items]                                      
Warrants to purchase shares             12,301                        
Exercise price             $ 12.05                        
Expiration date             Aug. 10, 2030                        
Number of shares isssued                         26,143            
Precision Healing Inc [Member]                                      
Loss Contingencies [Line Items]                                      
Cash consideration             $ 125,966                        
Payments receive             $ 10,000,000.0                        
Precision Healing [Member]                                      
Loss Contingencies [Line Items]                                      
Payments receive                 $ 10,000,000.0                    
2009 [Member] | Resorbable Bone Hemostat [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty percentage                             2.00%        
Rochal [Member]                                      
Loss Contingencies [Line Items]                                      
Payment of cash               $ 500,000                      
Accredited Investors [Member]                                      
Loss Contingencies [Line Items]                                      
Issuance of shares             165,738                        
Nonaccredited Investors [Member]                                      
Loss Contingencies [Line Items]                                      
Share price                                     $ 30.75
Minimum [Member]                                      
Loss Contingencies [Line Items]                                      
Proceeds from royalties received                             $ 201,000        
Minimum [Member] | 2009 [Member] | Resorbable Bone Hemostat [Member]                                      
Loss Contingencies [Line Items]                                      
Payments for royalties                             201,000        
Precision Healing [Member]                                      
Loss Contingencies [Line Items]                                      
Payment in cash             $ 600,000                        
Share price             $ 27.13   $ 27.13                    
Wound Care Solutions Limited [Member]                                      
Loss Contingencies [Line Items]                                      
Net income         $ 242,000   $ 220,000       $ 200,000                
Wound Care Solutions Limited [Member] | 2021 Through 2024 [Member]                                      
Loss Contingencies [Line Items]                                      
Net income, percentage                     10.00%                
Cost of Sales [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty expense                       9,209   432,809 1,060,035 1,245,775      
Annual royalty obligation                             16,080        
Sub License Agreement [Member]                                      
Loss Contingencies [Line Items]                                      
License agreement and royalties description       In August 2018, the Company entered into the Sublicense Agreement with CGI Cellerate RX to distribute CellerateRX Surgical and HYCOL products into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the Company pays royalties of 3-5% of annual collected net sales of CellerateRX Surgical and HYCOL. As amended in January 2021, the term of the sublicense extends through May 2050, with automatic successive year-to-year renewal terms thereafter so long as the Company’s Net Sales (as defined in the Sublicense Agreement) each year are equal to or in excess of $1,000,000. If the Company’s Net Sales fall below $1,000,000 for any year after the initial expiration date, CGI Cellerate RX will have the right to terminate the Sublicense Agreement upon written notice.                              
BIAKOS License Agreement [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty expense                       $ 32,499   $ 30,000 97,499 $ 90,000      
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member]                                      
Loss Contingencies [Line Items]                                      
Increase of royalties payable                             10,000        
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Minimum [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty percentage     2.00%                                
Payments for royalties                                 $ 120,000    
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty percentage     4.00%                                
Payments for royalties                             150,000        
BIAKOS Agreement [Member] | Maximum [Member]                                      
Loss Contingencies [Line Items]                                      
Payment for additional royalties                             $ 1,000,000        
ABF License Agreement [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty annual minimum percentage                             10.00%        
ABF License Agreement [Member] | Minimum [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty percentage                   2.00%                  
ABF License Agreement [Member] | Maximum [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty percentage                   4.00%                  
Payments for royalties                             $ 75,000        
Payment for additional royalties                             $ 500,000        
Debrider License Agreement [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty annual minimum percentage                             10.00%        
Payment of cash               $ 1,000,000                      
Debrider License Agreement [Member] | Minimum [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty percentage               2.00%                      
Payments for royalties               $ 100,000                      
Debrider License Agreement [Member] | Maximum [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty percentage               4.00%                      
Payments for royalties                             $ 150,000        
Payment for additional royalties                             $ 1,000,000        
Royalty Agreement [Member] | 2009 [Member] | Resorbable Bone Hemostat [Member]                                      
Loss Contingencies [Line Items]                                      
Royalty annual minimum percentage                             8.00%        
Purchase Agreement [Member]                                      
Loss Contingencies [Line Items]                                      
Acquisition consideration transferred           $ 7,600,000                          
cash           $ 1,600,000                          
Issuance of common stock for purchase of assets           291,686                          
Number of shares isssued           94,798                          
Payments to Acquire Productive Assets           $ 7,600,000                          
Services Agreement [Member]                                      
Loss Contingencies [Line Items]                                      
Purchase agreement description As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.